HGH Fragment 176-191: The Fat-Targeting Peptide That Leaves Insulin and IGF-1 Alone

Growth hormone is a 191-amino-acid, single-chain protein with a complex three-dimensional structure dominated by four alpha-helices. Its receptor (GHR) binding involves two distinct sites on the molecule: Site 1 and Site 2, which bind different regions of GHR in sequence to form a receptor dimer that initiates signaling through JAK2/STAT5. The metabolic effects of GH — anabolism via IGF-1 induction, insulin resistance, and lipolysis — map to different structural domains.

The key structural insight of Fragment 176-191 research is that the C-terminal region of GH (residues 176–191) appears to independently activate lipolytic pathways in adipocytes, potentially via a mechanism distinct from canonical GHR binding. Fragment 176-191 binds the full-length GHR with extremely low affinity — insufficient to stimulate hepatic IGF-1 production or trigger JAK2/STAT5 signaling at relevant concentrations. Yet it demonstrably stimulates lipolysis in adipose tissue, suggesting the fragment engages a different receptor interaction or pathway at the adipocyte level. ^[2]

What Fragment 176-191 Does Not Do

Understanding the compound's profile means understanding what it doesn't do:

• Does not stimulate hepatic JAK2/STAT5 signaling (the pathway driving IGF-1 production)
• Does not elevate serum IGF-1 levels (confirmed in multiple human studies)
• Does not cause insulin resistance (confirmed through glucose/insulin measurements in Phase II trials)
• Does not stimulate anabolic tissue growth beyond what its indirect fat-to-lean composition shift produces

This negative profile — what the compound doesn't do — is arguably as important as what it does do, because it defines a genuine pharmacological separation of the lipolytic and diabetogenic effects of growth hormone. ^[5]

In adipose tissue, HGH Fragment 176-191 has been shown in preclinical models to:

Stimulate Hormone-Sensitive Lipase (HSL)

The primary lipolytic enzyme in adipocytes is hormone-sensitive lipase (HSL), which hydrolyzes stored triglycerides into free fatty acids and glycerol. Fragment 176-191 administration in animal models increases HSL activity in adipose tissue — the same downstream effector that catecholamines activate via the β-adrenergic/cAMP/PKA pathway. This HSL activation drives mobilization of stored fat for peripheral oxidation. ^[1]

Inhibit Lipogenesis

Alongside lipolytic stimulation, the fragment has been reported to reduce lipogenesis — fat cell storage activity — potentially via effects on lipoprotein lipase (LPL) activity. This dual action (more breakdown, less synthesis) creates a favorable substrate flux in adipose tissue that full-length GH does not achieve without the accompanying insulin resistance.

Increase Whole-Body Fat Oxidation

The Heffernan et al. (2001) study in obese mice demonstrated that chronic treatment with Fragment 176-191 significantly increased whole-body fat oxidation (measured by respiratory quotient) and reduced visceral fat mass — without hyperglycemia or IGF-1 elevation seen with full-length GH at equivalent lipolytic doses. This was the definitive proof-of-concept for the functional separation claim. ^[1]

Fragment 176-191 was taken into pharmaceutical development under the name AOD9604 (Anti-Obesity Drug 9604) by Australian company Metabolic Pharmaceuticals. The clinical program was extensive, completing multiple Phase I safety studies and a large Phase IIb trial. ^[4]

Phase IIb Trial: Design and Results

The AOD9604 Phase IIb trial enrolled over 300 obese adults at multiple sites, comparing AOD9604 at daily doses of 1 mg and 2 mg to placebo over 12 weeks. Key findings from the clinical program:

• Safety: Well-tolerated at all doses — no significant adverse events compared to placebo across multiple trials
• No diabetogenic effect: Glucose, insulin, and HbA1c were unchanged from baseline and vs. placebo — the critical safety confirmation
• No IGF-1 elevation: Serum IGF-1 levels were unchanged, confirming the fragment's predicted lack of GHR/JAK2/STAT5 signaling in humans
• Efficacy: Weight loss numerically favored AOD9604, but the difference from placebo did not reach statistical significance in the primary endpoint

Why AOD9604 Didn't Get Approved

The clinical program did not support regulatory approval for obesity treatment. The modest weight loss advantage over placebo (approximately 1–2 kg across studies) was insufficient to justify approval, particularly against the competitive backdrop of GLP-1 agonists that were beginning to demonstrate dramatically larger effect sizes. The compound was safe but the efficacy story wasn't compelling enough for the regulatory bar in a competitive therapeutic landscape. ^[4]

However, the clinical data remains scientifically valuable precisely because it confirmed in humans what animal studies predicted: Fragment 176-191/AOD9604 does not affect glucose, insulin, or IGF-1. For a fragment of growth hormone, that safety profile is genuinely remarkable.

HGH Fragment 176-191 occupies a fundamentally different research niche than GH secretagogues like CJC-1295, Ipamorelin, or Hexarelin. The distinction matters for protocol design:

• GH secretagogues (CJC-1295, Ipamorelin, Hexarelin) stimulate the pituitary to release endogenous GH — elevating GH pulses, which then stimulate IGF-1 production. They affect the full GH/IGF-1 axis with all its downstream effects including anabolism, body composition changes, and at supraphysiologic levels, potential insulin resistance.
• HGH Fragment 176-191 bypasses the pituitary axis entirely, delivering a selective lipolytic signal to adipose tissue without stimulating IGF-1 or causing insulin resistance. It's not a growth hormone releaser — it's a selective fragment with a specific, domain-mapped adipose tissue action. ^[2][5]

For research focused specifically on adipose tissue biology, visceral fat metabolism, or the dissociation of GH's anabolic and metabolic effects, Fragment 176-191 provides a pharmacological tool that GH secretagogues cannot replicate. Researchers wanting to isolate lipolytic signaling from the anabolic effects of the GH axis have essentially one tool that achieves this from the GH peptide family: Fragment 176-191.

HGH Fragment 176-191 is commercially available through multiple established research peptide suppliers. Given the compound's relatively short amino acid sequence (16 residues), HPLC purity confirmation and mass spectrometry identity verification are both achievable and should be required from any supplier. COAs should document purity ≥98% and confirm the molecular weight corresponding to the fragment sequence.

HGH Fragment 176-191 represents a genuinely interesting case study in domain-selective pharmacology: a fragment of a larger hormone that dissociates two of its key biological activities — lipolysis and diabetogenesis — through structural truncation. The mechanism is real, the preclinical evidence is solid, and the clinical safety data is unusually robust for a research peptide, backed by multiple Phase I/II studies and an FDA GRAS determination. ^[4]

What the compound doesn't have is a proven clinical efficacy story in humans beyond the modest weight loss trends seen in AOD9604 trials. The GLP-1 agonist revolution has largely moved the obesity treatment landscape toward agents with much larger effect sizes, leaving Fragment 176-191 in a research niche rather than a mainstream therapeutic role. For the research community, however, that niche is scientifically valuable: no other peptide achieves selective adipose lipolysis with zero IGF-1 or insulin signaling effects.

For researchers studying adipose tissue biology, fat oxidation mechanisms, the pharmacology of GH structural domains, or the metabolic consequences of selective lipolytic activation without systemic anabolic effects, HGH Fragment 176-191 remains a scientifically compelling and practically accessible tool.

For the broader growth hormone secretagogue axis, see PeptideWiki's CJC-1295 + Ipamorelin Research Guide. For GLP-1 metabolic peptides with the largest human efficacy evidence base, see the GLP-1 Peptide Research Guide 2026. For GHRP mechanisms including the most potent secretagogue, see the Hexarelin Research Guide.